Skip to main content

Table 3 Immunoreactivity of HNF-1B in PDAC and non-pancreatic carcinomas

From: Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma

Cancer type

Total No.

HNF-1B +

Stain pattern

Fisher’s exact p-value

Pancreatic primary

127

107 (84.3%)

C, N, M

ref

Cholangiocarcinoma

15

13 (86.7%)

C, N, M

.81

Ampullary

18

13 (72%)

C, N, M

.21

Gallbladder

14

13 (92.9%)

C, N, M

.69

Colorectal

39

0

<.001

Hepatocellular

20

0

<.001

Esophagus

11

3 (27.3%)

C, N

<.001

Stomach

14

9 (64.3%)

C, N

.13

Lung adenocarcinoma

24

6 (25%)

C, N

<.001

Lung Squamous cell

10

0

<.001

Breast

20

0

<.001

Bladder

18

7 (38.9%)

C, N

<.001

Prostate

15

4 (26.7%)

C, N

<.001

Kidney

21

16 (76.2%)

N

.35

Ovary

18

14 (77.8%)

N, C

.50

Uterus

21

10 (47.6%)

N, C

<.001

Metastatic PDAC

17

16 (94.1%)

N, C

 

Total No.

422

   
  1. Abbreviations: PDAC, pancreatic ductal adenocarcinoma;
  2. SCC squamous cell carcinoma, C cytoplasmic, N nuclear, M membranous